These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2785092)

  • 21. Erythema dyschromicum perstans in prepubertal children.
    Silverberg NB; Herz J; Wagner A; Paller AS
    Pediatr Dermatol; 2003; 20(5):398-403. PubMed ID: 14521555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of the administration of B663 [G 30 320, Lamprene, clofazimine (Geigy)] on three groups of lepromatous and borderline of leprosy.
    Rodriguez JN; Abalos RM; Reich CV; Tolentino JG
    Int J Lepr Other Mycobact Dis; 1974; 42(3):276-88. PubMed ID: 4617715
    [No Abstract]   [Full Text] [Related]  

  • 23. Erythema dyschromicum perstans in phototype II women: three unusual clinical cases studied with electron microscopy.
    Persechino S; Caperchi C; Cortesi G; Persechino F; Raffa S; Pulcini F; Tammaro A; Torrisi MR
    Eur J Dermatol; 2011; 21(2):261-2. PubMed ID: 21382781
    [No Abstract]   [Full Text] [Related]  

  • 24. Limitations of clofazimine in the treatment of lepra reactions.
    Mishra B; Girdhar BK
    Indian J Lepr; 1986; 58(1):73-8. PubMed ID: 3746000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erythema Dyschromicum Perstans Response to Isotretinoin.
    Wang F; Zhao YK; Wang Z; Liu JH; Luo DQ
    JAMA Dermatol; 2016 Jul; 152(7):841-2. PubMed ID: 26933923
    [No Abstract]   [Full Text] [Related]  

  • 26. Erythema dyschromicum perstans.
    Knox JM; Dodge BG; Freeman RG
    Arch Dermatol; 1968 Mar; 97(3):262-72. PubMed ID: 5641329
    [No Abstract]   [Full Text] [Related]  

  • 27. Clofazimine (Lamprene, B663) in the treatment of lepromatous leprosy in the United Kingdom. A 12 year review of 31 cases, 1966-1978.
    Browne SG; Harman DJ; Waudby H; McDougall AC
    Int J Lepr Other Mycobact Dis; 1981 Jun; 49(2):167-76. PubMed ID: 7196886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The antileprotic action of clofazimine (B663, G30, 320, Lamprene).
    Azulay RD; da Silva NC; Zeo A; Portela AB; Franca JC; Peluso LL
    Int J Lepr Other Mycobact Dis; 1974; 42(1):13-8. PubMed ID: 4607163
    [No Abstract]   [Full Text] [Related]  

  • 29. Role of rifampin and clofazimine ointments in the treatment of leprosy.
    Venkateswarlu B; Venkataramana D; Rao AV; Prabhakar MC; Reddy BM
    Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):269-70. PubMed ID: 1522368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-ablative 1550 nm fractional laser therapy not effective for erythema dyschromicum perstans and postinflammatory hyperpigmentation: a pilot study.
    Kroon MW; Wind BS; Meesters AA; Wolkerstorfer A; van der Veen JP; Bos JD; Van der Wal AC; Beek JF
    J Dermatolog Treat; 2012 Oct; 23(5):339-44. PubMed ID: 21756152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clofazimine and dapsone--a combination therapy in erythema nodosum leprosum syndrome.
    Dutta RK
    Lepr India; 1980 Apr; 52(2):252-9. PubMed ID: 7453140
    [No Abstract]   [Full Text] [Related]  

  • 32. Erythema dyschromicum perstans and lichen planus: are they related?
    Berger RS; Hayes TJ; Dixon SL
    J Am Acad Dermatol; 1989 Aug; 21(2 Pt 2):438-42. PubMed ID: 2754077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erythema dyschromicum perstans in early childhood.
    Lee SJ; Chung KY
    J Dermatol; 1999 Feb; 26(2):119-21. PubMed ID: 10091483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erythema dyschromicum perstans in children: a report of 14 cases.
    Torrelo A; Zaballos P; Colmenero I; Mediero IG; de Prada I; Zambrano A
    J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):422-6. PubMed ID: 15987286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erythema dyschromicum perstans showing resolution in an adult.
    Antonov NK; Braverman I; Subtil A; Halasz CL
    JAAD Case Rep; 2015 Jul; 1(4):185-7. PubMed ID: 27051725
    [No Abstract]   [Full Text] [Related]  

  • 36. Erythema dyschromicum perstans in a Caucasian pediatric patient.
    Tisack AM; Huggins RH; Lim HW
    J Drugs Dermatol; 2013 Jul; 12(7):819-20. PubMed ID: 23884499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erythema dyschromicum perstans: response to dapsone therapy.
    Kontochristopoulos G; Stavropoulos P; Panteleos D; Aroni K
    Int J Dermatol; 1998 Oct; 37(10):796-8. PubMed ID: 9802694
    [No Abstract]   [Full Text] [Related]  

  • 38. Erythema Dyschromicum Perstans: Identical to Ashy Dermatosis or Not?
    Numata T; Harada K; Tsuboi R; Mitsuhashi Y
    Case Rep Dermatol; 2015; 7(2):146-50. PubMed ID: 26351421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erythema dyschromicum perstans.
    Tlougan BE; Gonzalez ME; Mandal RV; Kundu RV; Skopicki D
    Dermatol Online J; 2010 Nov; 16(11):17. PubMed ID: 21163168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.